Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles
Abstract
In this research we employed layered double hydroxide nanoparticles (LDHs) to simultaneously deliver an anticancer drug 5-fluorouracil (5-FU) and Allstars Cell Death siRNA (CD-siRNA) for effective cancer treatment. The strategy takes advantage of the LDH anion exchange capacity to intercalate 5-FU into its interlayer spacing and load siRNA on the surface of LDH nanoparticles. LDH nanoparticles have been previously demonstrated as an effective cellular delivery system for 5-FU and siRNA separately in various investigations. More excitedly, the combination of CD-siRNA and anticancer drug 5-FU with the same LDH particles significantly enhanced cytotoxicity to three cancer cell lines, e.g. MCF-7, U2OS and HCT-116, compared to the single treatment with either CD-siRNA or 5-FU. This enhancement is probably a result of coordinate mitochondrial damage process. Thus, the strategy to co-deliver siRNA and an anticancer drug by LDHs has great potential to overcome the drug resistance and enhance cancer treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Conventional strategy is to inhibit expression or activity of drug resistance-associated genes through siRNA or chemical inhibitors.
“The conventional strategy is to inhibit the expression or activity of these genes through small interfering RNA (siRNA) or chemical inhibitors [135–137].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [136]
The citation lists haven’t been fetched yet
References 41 · Cited by 304
- Authors
- Li, L., Gu, W., Chen, J., Chen, W., & Xu, Z. P.
- Affiliations
- The University of Queensland (AU)
- Corresponding author
- Gu, Wenyi
- Xu, Zhi P.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 35
- Issue
- 10
- Pages
- 3331-3339
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2047522840
- Cited by
- 304
- References
- 41
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 16 · 2023: 27 · 2022: 29 · 2021: 24 · 2020: 29 · 2019: 38 · 2018: 23 · 2017: 39 · 2016: 16 · 2015: 33 · 2014: 10
- FWCI
- 14.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biomaterials (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- Funders
- ARC Future Fellowship (FT120100813)
- ARC DP grant (DP120104792)
- University of Queensland Postdoctoral Fellowship and UQ early-career-research grant
- Topics
- Physical Sciences › Materials Science › Materials Chemistry › Layered Double Hydroxides Synthesis and Applications
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- layered double hydroxide nanoparticles, siRNA delivery, 5-fluorouracil, anion exchange, intercalation, mitochondrial damage, cancer cell lines, drug resistance, combination therapy
- MeSH terms
- Antineoplastic Agents, Humans, Hydroxides, Blotting, Western, Apoptosis, RNA, Small Interfering, Cell Line, Tumor, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review